Halozyme Therapeutics, Inc. (HALO)
110.19
-0.57
(-0.51%)
USD |
NASDAQ |
Sep 04, 16:00
109.96
-0.23
(-0.21%)
After-Hours: 20:00
Halozyme Therapeutics SG&A Expense (TTM) : 238.00M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 238.00M |
| March 31, 2026 | 222.61M |
| December 31, 2025 | 207.09M |
| September 30, 2025 | 172.31M |
| June 30, 2025 | 167.47M |
| March 31, 2025 | 161.56M |
| December 31, 2024 | 154.34M |
| September 30, 2024 | 149.69M |
| June 30, 2024 | 143.72M |
| March 31, 2024 | 146.96M |
| December 31, 2023 | 149.18M |
| September 30, 2023 | 149.32M |
| June 30, 2023 | 148.52M |
| March 31, 2023 | 167.05M |
| December 31, 2022 | 143.53M |
| September 30, 2022 | 119.55M |
| June 30, 2022 | 98.25M |
| March 31, 2022 | 53.10M |
| December 31, 2021 | 50.32M |
| September 30, 2021 | 46.98M |
| June 30, 2021 | 45.51M |
| March 31, 2021 | 44.16M |
| December 31, 2020 | 45.74M |
| September 30, 2020 | 59.24M |
| June 30, 2020 | 65.52M |
| Date | Value |
|---|---|
| March 31, 2020 | 71.88M |
| December 31, 2019 | 77.25M |
| September 30, 2019 | 71.35M |
| June 30, 2019 | 68.24M |
| March 31, 2019 | 65.25M |
| December 31, 2018 | 60.80M |
| September 30, 2018 | 57.54M |
| June 30, 2018 | 56.01M |
| March 31, 2018 | 54.76M |
| December 31, 2017 | 53.82M |
| September 30, 2017 | 51.27M |
| June 30, 2017 | 49.54M |
| March 31, 2017 | 47.66M |
| December 31, 2016 | 45.85M |
| September 30, 2016 | 44.22M |
| June 30, 2016 | 42.84M |
| March 31, 2016 | 41.44M |
| December 31, 2015 | 40.03M |
| September 30, 2015 | 37.79M |
| June 30, 2015 | 36.15M |
| March 31, 2015 | 35.09M |
| December 31, 2014 | 35.94M |
| September 30, 2014 | 36.95M |
| June 30, 2014 | 36.49M |
| March 31, 2014 | 35.04M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Incyte Corp. | 1.399B |
| AVITA Medical, Inc. | 81.89M |
| BioCryst Pharmaceuticals, Inc. | 328.11M |
| Neurocrine Biosciences, Inc. | 1.352B |
| Iovance Biotherapeutics, Inc. | 149.18M |